SUPPLEMENT
Q1 2020 — Reconciliation of Non-GAAP Financial Measures
Q1 2020PDF · 4 pages199 KB
Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2020 2019 Net Earnings, after tax- as reported $5,796 $3,749 Pre-tax Adjustments Intangible Asset Amortization expense 1,118 1,130 Litigation expense 120 423 IPR&D - 890 Restructuring related 118 90 Acquisition and Integration related ¹ (962) 67 Unrealized (gains)/losses on securities 327 (158) Medical Device Regulation 2 14 - Other - 3 Tax Adjustments Tax impact on special item adjustments 3 (267) (533) Tax legislation and related impacts (110) - Adjusted Net Earnings, after tax $6,154 $5,661 Average shares outstanding (Diluted) 2,671.0 2,698.8 Adjusted net earnings per share (Diluted) $2.30 $2.10 Operational adjusted net earnings per share (Diluted) $2.32 Notes: 1 2 3 First Quarter The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings . Acquisition and integration related costs for the first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance. -- 1 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 9.2% 8.7% (8.2)% 3.3% U.S. 21.0% 8.6% (6.8)% 5.6% International 0.3% 8.8% (9.4)% 1.0% WW Currency (2.1) (1.4) (1.3) (1.5) U.S. - - - - International (3.6) (3.2) (2.5) (3.0) WW Operational 11.3% 10.1% (6.9)% 4.8% U.S. 21.0% 8.6% (6.8)% 5.6% International 3.9% 12.0% (6.9)% 4.0% Skin Health / Beauty Dr. Ci Labo - Japan (0.4) (0.1) U.S. 0.0 0.0 International (0.7) (0.1) General Surgery Advanced Sterilization Products 2.1 0.8 U.S. 2.7 0.9 International 1.6 0.6 Baby Care Baby Center 0.3 0.0 U.S. 0.8 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures (0.2) 0.1 (0.1) 0.0 U.S. 0.0 0.1 (0.2) 0.0 International (0.3) 0.0 0.1 0.0 WW Adjusted Operational 11.0% 10.2% (4.8)% 5.6% U.S. 21.7% 8.7% (4.3)% 6.7% International 2.8% 12.0% (5.3)% 4.5% Adjusted Operational Sales Growth FIRST QUARTER 2020 ACTUAL vs. 2019 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income Before Tax by Segment $ 770 741 3,834 2,331 2,025 1,497 (120) (147) 6,509 4,422 % to Sales 21.2% 22.3% 34.4% 22.8% 34.1% 23.2% -0.6% -0.7% 31.5% 22.1% Intangible asset amortization 100 79 771 807 247 244 - - 1,118 1,130 In-process research and development - - - 890 - - - - - 890 Litigation expense, net - 8 93 325 27 90 - - 120 423 Unrealized loss/(gain) on securities 1 (4) 314 (143) 12 (11) - - 327 (158) Restructuring related 18 7 20 25 80 58 - - 118 90 Acquisition and integration related - - 9 39 (971) 28 - - (962) 67 Medical Device Regulation - - - - 14 - - - 14 - Other - - - - - 3 - - - 3 Adjusted Income Before Tax by Segment $ 889 831 5,041 4,274 1,434 1,909 (120) (147) 7,244 6,867 % to Sales 24.5% 25.0% 45.3% 41.7% 24.2% 29.6% -0.6% -0.7% 35.0% 34.3% *Estimated as of 04/14/2020. Q1 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 3 of 4 -- First Quarter Acquistion and First Quarter March 29, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Integration related (1) Medical Device Regulation Other March 29, 2020 Non-GAAP Cost of products sold 7,062 $ (1,118) (15) (14) 5,915 Other (Income) / Expense (679) - (120) (45) 962 (327) (209) In-process research and development - - Restructuring 58 (58) - Provision for taxes on income 713 146 20 21 3 75 2 110 1,090 Net Earnings 5,796 972 100 97 (965) 252 12 (110) 6,154 First Quarter Acquistion and First Quarter March 31, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Integration related (2) Medical Device Regulation Other March 31, 2019 Non-GAAP Cost of products sold 6,615 $ (1,130) (23) 5,462 Other (Income) / Expense (22) (423) (31) (67) 158 (3) (388) In-process research and development 890 (890) - Restructuring 36 (36) - Provision for taxes on income 673 284 81 187 15 7 (33) (8) 1,206 Net Earnings 3,749 846 342 703 75 60 (125) 11 5,661 (2) Includes $39M related to Actelion and $28M related to AMO (Pre-tax) (1) Primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Unrealized (loss)/gain on securities In-process research and development Tax legislation and related impacts -- 4 of 4 --